24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Prostate Cancer
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:15
Israel grounds civilian drones controlled by fiber-optic cables and SIM cards
15:46
Israel’s weapons remain in demand, but politics may decide who buys them
15:21
Israeli firm accused of using online ads to track Starlink users worldwide
13:04
“Intel will be among the first names people think of in quantum computing,” says Classiq CEO
More stories
Buzz
Most popular
Daily
Weekly
1
Microsoft offers buyouts to 60,000 workers but says layoffs remain an option
2
Intel to acquire Israeli quantum startup Classiq for $2.3 billion
3
Palantir CEO says Israel is the "minor exception" in AI race dominated by U.S. and China
4
Classiq founders set to pocket up to $100 million each in Intel’s $2.3 billion deal
5
One-year-old AI unicorn Unconventional acquires Israeli chipmaker NeuReality
More news
Prostate Cancer
1 stories about Prostate Cancer
Is it time to reconsider PSA tests for Prostate Cancer?
01.09.22
|
Itay Barnea
“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect